Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H.

J Clin Oncol. 2008 Nov 10;26(32):5204-12. doi: 10.1200/JCO.2007.15.6331. Epub 2008 Oct 6.

PMID:
18838713
2.

Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.

Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, Kato T.

Jpn J Clin Oncol. 2012 Aug;42(8):742-7. doi: 10.1093/jjco/hys076. Epub 2012 May 23.

PMID:
22628612
3.

Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.

Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J.

Ann Oncol. 2007 Nov;18(11):1906-7. No abstract available.

PMID:
17993633
4.

Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.

Muriel C, Esteban E, Corral N, Fonseca PJ, Luque M, Berros JP, Fernández Y, Blay P, Fra J, Villanueva N, Sanmamed M, Pardo P, Izquierdo M, Vieitez JM, Estrada E, Lacave ÁJ.

Clin Transl Oncol. 2010 Aug;12(8):562-7. doi: 10.1007/s12094-010-0554-0.

PMID:
20709657
5.

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.

Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.

PMID:
19558553
6.

Hypothyroidism in patients with renal cell carcinoma: blessing or curse?

Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC.

Cancer. 2011 Feb 1;117(3):534-44. doi: 10.1002/cncr.25422. Epub 2010 Sep 15.

7.

Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.

La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.

Am J Clin Oncol. 2010 Jun;33(3):217-20. doi: 10.1097/COC.0b013e3181a650a6.

PMID:
19745694
8.
9.

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.

Pantaleo MA, Mandrioli A, Saponara M, Nannini M, Erente G, Lolli C, Biasco G.

BMC Cancer. 2012 Jun 11;12:231. doi: 10.1186/1471-2407-12-231.

10.

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA.

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525. No abstract available.

PMID:
18711201
11.

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.

Di Fiore F, Rigal O, Ménager C, Michel P, Pfister C.

Br J Cancer. 2011 Dec 6;105(12):1811-3. doi: 10.1038/bjc.2011.507. Epub 2011 Nov 17.

12.

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.

Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS.

Clin Cancer Res. 2015 Sep 15;21(18):4048-54. doi: 10.1158/1078-0432.CCR-15-0215. Epub 2015 May 12.

13.

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.

Lee JL, Park I, Park K, Park S, Ahn Y, Ahn JH, Kim TW, Ahn S, Song C, Hong JH, Kim CS, Ahn H.

J Cancer Res Clin Oncol. 2012 Apr;138(4):687-93. doi: 10.1007/s00432-012-1148-8. Epub 2012 Jan 12.

PMID:
22237457
14.

Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.

Miyake H, Imai S, Harada K, Fujisawa M.

Clin Genitourin Cancer. 2016 Feb;14(1):e19-24. doi: 10.1016/j.clgc.2015.08.002. Epub 2015 Aug 15.

PMID:
26382221
15.

[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].

Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.

Aktuelle Urol. 2009 Jan;40(1):31-6. doi: 10.1055/s-2008-1038176. Epub 2009 Jan 28. German.

PMID:
19177319
16.

Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?

Lenihan DJ.

J Clin Oncol. 2008 Nov 10;26(32):5154-5. doi: 10.1200/JCO.2008.18.5439. Epub 2008 Oct 6. No abstract available.

PMID:
18838702
17.

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.

Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H.

Eur Urol. 2008 Dec;54(6):1373-8. doi: 10.1016/j.eururo.2008.07.051. Epub 2008 Aug 8.

PMID:
18692304
18.

Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.

Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V.

Eur Urol. 2009 Jun;55(6):1430-8. doi: 10.1016/j.eururo.2008.10.021. Epub 2008 Oct 18.

PMID:
18950936
19.

Sequential sorafenib and sunitinib for renal cell carcinoma.

Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B.

J Urol. 2009 Jul;182(1):29-34; discussion 34. doi: 10.1016/j.juro.2009.02.119. Epub 2009 May 17.

PMID:
19447417
20.

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

Ravaud A, Sire M.

Ann Oncol. 2009 May;20(5):966-7; author reply 967. doi: 10.1093/annonc/mdp201. No abstract available.

PMID:
19403939

Supplemental Content

Support Center